Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Lifetime Risk of Heart Failure and Trends in Incidence Rates Among Individuals With Type 2 Diabetes Between 1995 and 2018

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Contacts With the Health Care System Before Out-of-Hospital Cardiac Arrest

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Incidence of Infective Endocarditis Among Patients With Tetralogy of Fallot

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Treatment of Older Patients with Atrial Fibrillation by Morbidity Burden

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background There are limited data on the lifetime risk of heart failure (HF) in people with type 2 diabetes and how incidence has changed over time. We estimated the cumulative incidence and incidence rates of HF among Danish adults with type 2 diabetes between 1995 and 2018 using nationwide data. Methods and Results In total, 398 422 patients (49% women) with type 2 diabetes were identified. During follow-up, 36 400 (9%) were diagnosed with HF and 121 459 (30%) were censored due to death. Using the Aalen-Johansen estimators, accounting for the risk of death, the estimated residual lifetime risk of HF at age 50 years was calculated as 24% (95% CI 22%-27%) in women and 27% (25%-28%) in men. During the observational period, the proportion of patients treated with statins, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and metformin increased from <30% to >60%. Similarly, the annual incidence rates of HF decreased significantly, with declines being greater in older versus younger individuals (5% versus 2% in age >50 versus ≤50 years, respectively; P<0.0001) and in women versus men (5% versus 4%, P=0.02), but similar in patients with and without IHD (4% versus 4%, P=0.53). Conclusions The current lifetime risk of HF in type 2 diabetes approximates 1 in 4 for men and women. Paralleled by an increase in use of evidence-based pharmacotherapy over the past decades, the risk of developing HF has declined across several subgroups and regardless of underlying IHD, suggesting that optimal diabetes treatment can mitigate HF risk.

OriginalsprogEngelsk
Artikelnummere021230
TidsskriftJournal of the American Heart Association
Vol/bind10
Udgave nummer21
Sider (fra-til)e021230
ISSN2047-9980
DOI
StatusUdgivet - 2 nov. 2021

ID: 68664765